Literature DB >> 11752138

Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins.

Paulo H Verardi1, Fatema H Aziz, Shabbir Ahmad, Leslie A Jones, Berhanu Beyene, Rosemary N Ngotho, Henry M Wamwayi, Mebratu G Yesus, Berhe G Egziabher, Tilahun D Yilma.   

Abstract

Rinderpest is an acute and highly contagious viral disease of ruminants, often resulting in greater than 90% mortality. We have constructed a recombinant vaccinia virus vaccine (v2RVFH) that expresses both the fusion (F) and hemagglutinin (H) genes of rinderpest virus (RPV) under strong synthetic vaccinia virus promoters. v2RVFH-infected cells express high levels of the F and H glycoproteins and show extensive syncytium formation. Cattle vaccinated intramuscularly with as little as 10(3) PFU of v2RVFH and challenged 1 month later with a lethal dose of RPV were completely protected from clinical disease; the 50% protective dose was determined to be 10(2) PFU. Animals vaccinated with v2RVFH did not develop pock lesions and did not transmit the recombinant vaccinia virus to contact animals. Intramuscular vaccination of cattle with 10(8) PFU of v2RVFH provided long-term sterilizing immunity against rinderpest. In addition to being highly safe and efficacious, v2RVFH is a heat-stable, inexpensive, and easily administered vaccine that allows the serological differentiation between vaccinated and naturally infected animals. Consequently, mass vaccination of cattle with v2RVFH could eradicate rinderpest.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752138      PMCID: PMC136817          DOI: 10.1128/jvi.76.2.484-491.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody.

Authors:  Y d Zhu; P Rota; L Wyatt; A Tamin; S Rozenblatt; N Lerche; B Moss; W Bellini; M McChesney
Journal:  Virology       Date:  2000-10-10       Impact factor: 3.616

2.  Disturbances in gamma globulin synthesis as experiments of nature.

Authors:  R A GOOD; S J ZAK
Journal:  Pediatrics       Date:  1956-07       Impact factor: 7.124

3.  Rinderpest epidemic in wild ruminants in Kenya 1993-97.

Authors:  R A Kock; J M Wambua; J Mwanzia; H Wamwayi; E K Ndungu; T Barrett; N D Kock; P B Rossiter
Journal:  Vet Rec       Date:  1999-09-04       Impact factor: 2.695

4.  The duration of immunity in cattle following inoculation of rinderpest cell culture vaccine.

Authors:  W Plowright
Journal:  J Hyg (Lond)       Date:  1984-06

5.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

6.  Microtitre techniques for the assay of rinderpest virus and neutralising antibody.

Authors:  P B Rossiter; D M Jessett
Journal:  Res Vet Sci       Date:  1982-03       Impact factor: 2.534

7.  Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity.

Authors:  P H Verardi; L A Jones; F H Aziz; S Ahmad; T D Yilma
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Long-term protective immunity to rinderpest in cattle following a single vaccination with a recombinant vaccinia virus expressing the virus haemagglutinin protein.

Authors:  K Ohishi; K Inui; T Barrett; K Yamanouchi
Journal:  J Gen Virol       Date:  2000-06       Impact factor: 3.891

9.  Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.

Authors:  T J Wiktor; R I Macfarlan; K J Reagan; B Dietzschold; P J Curtis; W H Wunner; M P Kieny; R Lathe; J P Lecocq; M Mackett
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

10.  Expression of rabies virus glycoprotein from a recombinant vaccinia virus.

Authors:  M P Kieny; R Lathe; R Drillien; D Spehner; S Skory; D Schmitt; T Wiktor; H Koprowski; J P Lecocq
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

View more
  14 in total

1.  Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo.

Authors:  Fatema A Legrand; Paulo H Verardi; Kenneth S Chan; Yue Peng; Leslie A Jones; Tilahun D Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-10       Impact factor: 11.205

2.  Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice.

Authors:  James F Papin; Paulo H Verardi; Leslie A Jones; Francisco Monge-Navarro; Aaron C Brault; Michael R Holbrook; Melissa N Worthy; Alexander N Freiberg; Tilahun D Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-23       Impact factor: 11.205

3.  Recombinant adenovirus expressing the haemagglutinin of Peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR.

Authors:  Rebecca Herbert; Jana Baron; Carrie Batten; Michael Baron; Geraldine Taylor
Journal:  Vet Res       Date:  2014-02-26       Impact factor: 3.683

4.  Lower levels of gamma interferon expressed by a pseudotyped single-cycle simian immunodeficiency virus enhance immunogenicity in rats.

Authors:  Yue Peng; Fan-ching Lin; Paulo H Verardi; Leslie A Jones; Tilahun D Yilma
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

5.  MVA recombinants expressing the fusion and hemagglutinin genes of PPRV protects goats against virulent challenge.

Authors:  Dev Chandran; Kolli Bhaktavatsala Reddy; Shahana Pallichera Vijayan; Parthasarthy Sugumar; Gudavalli Sudha Rani; Ponsekaran Santha Kumar; Lingala Rajendra; Villuppanoor Alwar Srinivasan
Journal:  Indian J Microbiol       Date:  2010-03-16       Impact factor: 2.461

6.  IL-18 expression results in a recombinant vaccinia virus that is highly attenuated and immunogenic.

Authors:  Paulo H Verardi; Fatema A Legrand; Kenneth S Chan; Yue Peng; Leslie A Jones; Tilahun D Yilma
Journal:  J Interferon Cytokine Res       Date:  2013-10-29       Impact factor: 2.607

7.  Assessment of the control measures of category A diseases of the Animal Health Law: Infection with rinderpest virus (Rinderpest).

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Hans Spoolder; Karl Ståhl; Antonio Velarde; Arvo Viltrop; Christoph Winckler; Kris De Clercq; Simon Gubbins; Genevieve Libeau; Andrea Gervelmeyer; Helen Clare Roberts
Journal:  EFSA J       Date:  2022-01-25

Review 8.  A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.

Authors:  Paulo H Verardi; Allison Titong; Caitlin J Hagen
Journal:  Hum Vaccin Immunother       Date:  2012-07-01       Impact factor: 3.452

9.  Replication-inducible vaccinia virus vectors with enhanced safety in vivo.

Authors:  Caitlin M O'Connell; Brittany Jasperse; Caitlin J Hagen; Allison Titong; Paulo H Verardi
Journal:  PLoS One       Date:  2020-04-02       Impact factor: 3.240

Review 10.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.